Albany Business Review: SUNY Poly spinoff commercializing research that could change the future of drug treatment
Albany Business Review
“The idea is to make it target-specific. So we don't make the drug; we make it better. We could use this to potentially get rid of those cells early, and that might prevent the disease from progressing."
The latest research is based on previous research by André Melendez, the interim dean of the College of Nanoscale Science and Engineering at SUNY Poly. He was previously awarded funding by the New York State Center for Advanced Technology in Nanomaterials and Nanoelectronics to explore how aging and nutrient deficiencies can lead to increased viral susceptibility."